Maternale Immunisierung | Gulf - ABRYSVO Brand Microsite

This site is intended only for healthcare professionals in UAE, Kuwait, Qatar, Bahrain, Oman.

Sign In or Register

Log Out

Our Medicines

Therapy Areas

Explore Content

Events

Downloadable materials

Videos

Let's Connect

Pfizer medical information

Maternal Immunisation

Maternal Immunisation Homepage

Safety Profile

Dosing

Older Adults

Older Adults Homepage

Safety Profile

Dosing

Preparation

Useful Resources

Older Adults

Older Adults Homepage

Safety Profile

Dosing

Videos

Materials

Disclaimer: This information is valid only for healthcare professionals in Bahrain, Oman, Qatar & UAE.

Abrysvo™ (Respiratory syncytial virus vaccine) is available, marketed and has a Health Registry only in Bahrain, Oman, Qatar & UAE. The advertising or promotion carried out for Abrysvo™ (Respiratory syncytial virus vaccine) is only directed to health professionals in Bahrain, Oman, Qatar & UAE.

Information on how to access Abrysvo™ (Respiratory syncytial virus vaccine) prescribing information and adverse event reporting can be found at the bottom of the page.

Please refer to the Summary of Product Characteristics before administering this vaccine

Most local and systemic reactions in maternal participants were mild to moderate in severity and resolved within 2-3 days of onset.¹

In pregnant women at 24-36 weeks of gestation, the most frequently reported adverse reactions were vaccination site pain (41%), headache (31%), and myalgia (27%).¹

Tabulated Adverse Events (AE) in pregnant women

Please refer to the SmPC for additional safety information.

No safety signals were detected in infants up to 24 months of age.¹

The incidences of AEs reported within 1 month after birth in infants were similar in the ABRYSVO group (37%) and the placebo group (35%).¹
The safety profile of ABRYSVO was evaluated in phase 3 clinical studies. Pregnant women (n=3,682) at 24-36 weeks of gestation were evaluated after receiving a single dose of vaccine.¹

Contraindications¹

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 of the SmPC.

Special warnings and precautions for use¹

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity and anaphylaxis

Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Anxiety-related reactions

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from fainting.

Concurrent illness

Vaccination should be postponed in individuals suffering from an acute febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

Thrombocytopenia and coagulation disorders

ABRYSVO should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding or bruising may occur following an intramuscular administration to these individuals

lmmunocompromised individuals

The efficacy and safety of the vaccine have not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of ABRYSVO may be lower in immunosuppressed individuals.

ABRYSVO - Maternal Immunisation

Learn more about maternal immunisation 1vith ABRYSVO

Learn more

Preparation of ABRYSVO

Watch a video on how to prepare ABRYSVO for administration.

Learn more

Dosing - Pregnant Women

Find out more about the dosing information of ABRYSVO for maternal patients.

Learn more

1. Abrysvo™ (Respiratory syncytial virus vaccine) Local Product Document Revision Date: August 2023 for Oman, Qatar, UAE and October 2024 for Bahrain.

Prescribing Information:

Bahrain Prescribing Information
Oman Prescribing Information
Qatar Prescribing Information
UAE Prescribing Information

PP-A1G-BHR-0040

This information is valid only for healthcare professionals in Bahrain, Oman, Qatar & UAE.

Report Adverse Events

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro account

PfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign In or Register

Account

Sign Out

i- The product information provided in this site is intended only for Healthcare Professionals of UAE, Kuwait, Qatar, Bahrain, Oman.

ii- The information contained on this website is offered for educational purposes only and does not represent medical advice, diagnosis, treatment or a professional recommendation. Pfizer will not be responsible for the use or interpretation of the information by the user of the website.

iii- The products discussed herein may have a different product labeling than authorized in your country and may not be available in some territories.

PP-UNP-BHR-0298

You are now leaving PfizerPro

You are leaving the Pfizer Portal - would you like to continue?

You are now leaving PfizerPro

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd.

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to Pfizer medicines or
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021

You are now leaving Pfizer

You are now leaving Pfizerpro and will be directed to our provider to complete your registration. Any personal information that you may find pre-populated from your Pfizerpro profile, or you may provide, will be governed by our Privacy Policy. Your data will not be used for any other purpose.